pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 23·1 min read
save

David Reese to retire from Amgen

Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a role he created at Amgen in 2023 ...

Apr 23, 2026·read at Endpoints ↗

David Reese (Amgen via website) April 23, 2026 11:02 AM EDTUpdated 05:44 PM People David Reese to re­tire from Am­gen Lei Lei Wu News Reporter Long­time Am­gen leader David Reese is re­tir­ing at the end of June, Am­gen an­nounced Wednes­day evening. Reese, 63, cur­rent­ly serves as chief tech­nol­o­gy of­fi­cer, a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
85 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AMGEN5

related stories

  • Jun 10Ethyreal starts up with $101M and takes aim at a pair of immune diseasesBioPharma Dive
  • Jun 8Tango data add to growing momentum for pancreatic cancer drugsBioPharma Dive
  • Jun 5Study data convince Lundbeck to push new migraine drug forwardBioPharma Dive
  • Jun 4STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?STAT
  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive